Boston Scientific (NYSE:BSX) Hits New 12-Month Low After Analyst Downgrade

Shares of Boston Scientific Corporation (NYSE:BSX) hit a new 52-week low during mid-day trading on Tuesday after Stifel Nicolaus lowered their price target on the stock from $90.00 to $85.00. Stifel Nicolaus currently has a buy rating on the stock. Boston Scientific traded as low as $60.05 and last traded at $61.4330, with a volume of 2552167 shares trading hands. The stock had previously closed at $60.99.

Other analysts have also issued research reports about the stock. The Goldman Sachs Group dropped their price objective on shares of Boston Scientific from $98.00 to $93.00 and set a “buy” rating for the company in a report on Friday, March 27th. Citigroup reduced their target price on Boston Scientific from $94.00 to $87.00 and set a “buy” rating on the stock in a report on Tuesday, April 7th. Raymond James Financial reaffirmed an “outperform” rating and set a $88.00 price target (down from $97.00) on shares of Boston Scientific in a report on Monday, March 30th. Evercore cut their price objective on Boston Scientific from $112.00 to $96.00 and set an “outperform” rating for the company in a research report on Thursday, February 5th. Finally, Weiss Ratings lowered Boston Scientific from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Wednesday, February 4th. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat.com, Boston Scientific presently has a consensus rating of “Moderate Buy” and an average price target of $102.59.

Insider Buying and Selling at Boston Scientific

In related news, CEO Michael F. Mahoney sold 160,901 shares of the business’s stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average price of $93.49, for a total value of $15,042,634.49. Following the completion of the transaction, the chief executive officer owned 1,411,735 shares in the company, valued at $131,983,105.15. The trade was a 10.23% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 0.34% of the stock is currently owned by corporate insiders.

Key Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Unusually large call-option buying: investors purchased ~60,185 call options today (about a 154% jump vs. normal), signaling speculative bullish positioning or hedging ahead of catalysts such as earnings and potential regulatory wins.
• Positive Sentiment: Analyst backing and long-term upside remain: despite recent downdraft, many firms still carry Buy/Outperform ratings and the median analyst target across recent reports sits near $100, implying material upside from current levels. Wall Street Refuses to Blink
• Neutral Sentiment: Pre-earnings positioning and scheduled Q1 report: the company reports Q1 results Wednesday (pre-market), which is driving de-risking and volatility into the print — investors are positioning for guidance and procedure trends. Q1 2026 Earnings Preview
• Neutral Sentiment: Mixed analyst tweaks: Stifel trimmed its price target (now $85) but kept a Buy rating, and Truist slightly cut its PT to $90 while remaining constructive — these are modest downward revisions but not a shift to sell consensus. Boston Scientific Stock Is Trending Today
• Negative Sentiment: Surge of securities class-action notices and filings: multiple law firms (Pomerantz, Portnoy, Faruqi, Robbins, Rosen, Bernstein Liebhard, etc.) have announced suits or investor alerts tied to a July 23, 2025–Feb 3, 2026 class period and a May 4 lead-plaintiff deadline — this increases headline/legal risk and could pressure sentiment and costs. Pomerantz Investor Alert
• Negative Sentiment: Near-term technical/valuation pressure: coverage notes and commentary report BSX near a 52-week low with YTD weakness and some analysts trimming forecasts — these factors contribute to selling momentum ahead of earnings. 52-Week Low Coverage
• Negative Sentiment: Insider selling and institutional rebalances noted in data summaries may amplify negative sentiment when combined with legal headlines and uncertain near-term procedure trends. Quiver/Market Analysis

Hedge Funds Weigh In On Boston Scientific

Large investors have recently made changes to their positions in the company. Vanguard Group Inc. increased its position in Boston Scientific by 1.0% in the fourth quarter. Vanguard Group Inc. now owns 139,685,997 shares of the medical equipment provider’s stock worth $13,319,060,000 after purchasing an additional 1,436,550 shares during the period. State Street Corp lifted its position in Boston Scientific by 1.4% during the 4th quarter. State Street Corp now owns 65,846,059 shares of the medical equipment provider’s stock valued at $6,278,422,000 after purchasing an additional 920,495 shares during the period. Capital World Investors boosted its stake in shares of Boston Scientific by 1.9% in the 4th quarter. Capital World Investors now owns 27,151,575 shares of the medical equipment provider’s stock valued at $2,588,953,000 after purchasing an additional 502,627 shares during the last quarter. Norges Bank bought a new position in shares of Boston Scientific in the 4th quarter valued at about $2,199,395,000. Finally, Morgan Stanley grew its position in shares of Boston Scientific by 10.8% during the 4th quarter. Morgan Stanley now owns 22,960,556 shares of the medical equipment provider’s stock worth $2,189,289,000 after buying an additional 2,246,308 shares during the period. Institutional investors and hedge funds own 89.07% of the company’s stock.

Boston Scientific Stock Performance

The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.08 and a current ratio of 1.62. The company has a market cap of $88.37 billion, a price-to-earnings ratio of 30.65, a PEG ratio of 0.94 and a beta of 0.78. The firm’s 50-day moving average price is $69.04 and its 200 day moving average price is $86.31.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share for the quarter, beating the consensus estimate of $0.78 by $0.02. Boston Scientific had a net margin of 14.44% and a return on equity of 19.63%. The business had revenue of $5.29 billion for the quarter, compared to analyst estimates of $5.29 billion. During the same period in the prior year, the business posted $0.70 earnings per share. Boston Scientific’s revenue was up 15.9% compared to the same quarter last year. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. On average, sell-side analysts anticipate that Boston Scientific Corporation will post 3.45 EPS for the current year.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.